Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Dentsply, and Invivyd on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Dentsply Sirona, Inc. (NASDAQ: XRAY), and Invivyd, Inc. (NASDAQ: IVVD) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.

Dentsply Sirona, Inc. (NASDAQ: XRAY)

Bragar Eagel & Squire is investigating certain officers and directors of Dentsply Sirona, Inc. following a class action complaint that was filed against Dentsply on May 2, 2022.

The complaint alleges that, throughout the Class Period, Defendants orchestrated a scheme to inflate the Company’s revenue and earnings by manipulating its accounting for a distributor rebate program in order for senior executives to be eligible for significant cash and stock-based incentive compensation. In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period. As a result of Defendants’ misrepresentations, Dentsply’s common stock traded at artificially inflated prices during the Class Period.

To learn more about our investigation into Dentsply go to: https://bespc.com/cases/XRAY

Invivyd, Inc. (NASDAQ: IVVD)

Bragar Eagel & Squire is investigating certain officers and directors of Invivyd, Inc. following a class action complaint that was filed against Invivyd on January 31, 2023.

The plaintiff alleges that, the defendants failed to disclose that the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim ADG20 was effective against the Omicron variant were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron, that that defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis, and that ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

To learn more about our investigation into Invivyd go to: https://bespc.com/cases/IVVD

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.